September 30, 2026- Medtronic announced regulatory milestones for software used with two cardiac ablation platforms. This includes U.S. Food and Drug Administration (FDA) clearance and CE Mark for the latest Affera™ Prism-2 Mapping Software. The company also obtained CE Mark for the PulseSelect ProxBox™ Adapter with Proximity Indicator software. These milestones expand integrated mapping and tissue-proximity capabilities across the Medtronic cardiac ablation portfolio.